These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 26331221

  • 1. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E, Correia C, Freitas P, Nogueira C, Costa M, Saavedra A, Costa C, Carvalho D, Fontoura M.
    Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
    [Abstract] [Full Text] [Related]

  • 2. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M, Al Mutair A, Al Balwi M, Hussain K.
    Ann Saudi Med; 2010 Dec; 30(2):162-4. PubMed ID: 20220270
    [Abstract] [Full Text] [Related]

  • 3. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
    Zung A, Glaser B, Nimri R, Zadik Z.
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5504-7. PubMed ID: 15531505
    [Abstract] [Full Text] [Related]

  • 4. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM, Ješić MD, Maglajlić S, Sajić S, Necić S.
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [Abstract] [Full Text] [Related]

  • 5. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ.
    Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
    [Abstract] [Full Text] [Related]

  • 6. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
    Mancioppi V, Pozzi E, Zanetta S, Missineo A, Savastio S, Barbetti F, Mellone S, Giordano M, Rabbone I.
    Front Endocrinol (Lausanne); 2023 Nov; 14():1143736. PubMed ID: 37251668
    [Abstract] [Full Text] [Related]

  • 7. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
    Kim MS, Kim SY, Kim GH, Yoo HW, Lee DW, Lee DY.
    J Korean Med Sci; 2007 Aug; 22(4):616-20. PubMed ID: 17728498
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, Tessmann EH, Juliusson PB, Skrivarhaug T, Pearson ER, Flanagan SE, Babiker T, Thomas NJ, Shepherd MH, Ellard S, Klimes I, Szopa M, Polak M, Iafusco D, Hattersley AT, Njølstad PR, Neonatal Diabetes International Collaborative Group.
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [Abstract] [Full Text] [Related]

  • 9. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T, Vedovato N, Patel K, Thomas N, Finn R, Männikkö R, Chakera AJ, Flanagan SE, Shepherd MH, Ellard S, Ashcroft FM, Hattersley AT.
    Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
    [Abstract] [Full Text] [Related]

  • 10. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT, Neonatal Diabetes International Collaborative Group.
    N Engl J Med; 2006 Aug 03; 355(5):467-77. PubMed ID: 16885550
    [Abstract] [Full Text] [Related]

  • 11. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W, Tarasov AI, Gach A, Girard CA, Pietrzak I, Zubcevic L, Kusmierek J, Klupa T, Malecki MT, Ashcroft FM.
    Nat Clin Pract Neurol; 2007 Nov 03; 3(11):640-5. PubMed ID: 17982434
    [Abstract] [Full Text] [Related]

  • 12. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of KATP-Channel Neonatal Diabetes Mellitus in Vietnam National Children's Hospital.
    Ngoc CTB, Dien TM, De Franco E, Ellard S, Houghton JAL, Lan NN, Thao BP, Khanh NN, Flanagan SE, Craig ME, Dung VC.
    Front Endocrinol (Lausanne); 2021 Nov 03; 12():727083. PubMed ID: 34566892
    [Abstract] [Full Text] [Related]

  • 13. Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report.
    Heo JW, Kim SW, Cho EH.
    Diabetes Res Clin Pract; 2013 Apr 03; 100(1):e1-2. PubMed ID: 23434183
    [Abstract] [Full Text] [Related]

  • 14. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
    Dupont J, Pereira C, Medeira A, Duarte R, Ellard S, Sampaio L.
    J Pediatr Endocrinol Metab; 2012 Apr 03; 25(3-4):367-70. PubMed ID: 22768671
    [Abstract] [Full Text] [Related]

  • 15. [Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2].
    Ille J, Putarek NR, Radica A, Hattersley A, Ellard S, Dumić M.
    Lijec Vjesn; 2010 Apr 03; 132(3-4):90-3. PubMed ID: 20540435
    [Abstract] [Full Text] [Related]

  • 16. Comparison of diabetes phenotype in children and their mothers with permanent neonatal diabetes mellitus carrying the same KCNJ11 variants.
    Stanik J, Barak L, Dankovcikova A, Valkovicova T, Skopkova M, Gasperikova D.
    Endocr Regul; 2020 Nov 24; 54(4):260-265. PubMed ID: 33885251
    [Abstract] [Full Text] [Related]

  • 17. Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated KCNJ11 neonatal diabetes show predominance of non-KATP-channel pathways.
    Bowman P, McDonald TJ, Knight BA, Flanagan SE, Leveridge M, Spaull SR, Shields BM, Hammersley S, Shepherd MH, Andrews RC, Patel KA, Hattersley AT.
    BMJ Open Diabetes Res Care; 2019 Nov 24; 7(1):e000721. PubMed ID: 31908791
    [Abstract] [Full Text] [Related]

  • 18. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas.
    Itoh S, Matsuoka H, Yasuda Y, Miyake N, Suzuki K, Yorifuji T, Sugihara S.
    J Pediatr Endocrinol Metab; 2013 Nov 24; 26(1-2):143-6. PubMed ID: 23382304
    [Abstract] [Full Text] [Related]

  • 19. Sulfonylurea-responsive diabetes in childhood.
    Landau Z, Wainstein J, Hanukoglu A, Tuval M, Lavie J, Glaser B.
    J Pediatr; 2007 May 24; 150(5):553-5. PubMed ID: 17452235
    [Abstract] [Full Text] [Related]

  • 20. Molecular and clinical features of KATP -channel neonatal diabetes mellitus in Japan.
    Hashimoto Y, Dateki S, Hirose M, Satomura K, Sawada H, Mizuno H, Sugihara S, Maruyama K, Urakami T, Sugawara H, Shirai K, Yorifuji T.
    Pediatr Diabetes; 2017 Nov 24; 18(7):532-539. PubMed ID: 27681997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.